Tirzepatide vs. Ozempic vs. Mounjaro: The Real Comparison

The GLP-1 space has two dominant players right now: semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Both produce extraordinary weight loss by clinical standards. Both are available as compounded medications at a fraction of brand-name cost. Both have changed the obesity treatment landscape permanently.

But they're not the same drug. And the choice between them matters.

Here's what the science actually says — and what your physician needs to know about you to make the right call.

The Mechanism Difference (And Why It Matters)

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone naturally released after eating that signals satiety, slows gastric emptying, and stimulates insulin release. One receptor target. One primary mechanism.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It hits two targets simultaneously: GLP-1 receptors (same as semaglutide) plus GIP receptors (glucose-dependent insulinotropic polypeptide). GIP is another incretin hormone that works synergistically with GLP-1. This dual mechanism is why tirzepatide tends to produce greater weight loss.

Think of it this way: semaglutide is a precision instrument. Tirzepatide is a broader metabolic tool.

What the Data Actually Shows

Weight Loss Outcomes:

The STEP trials (semaglutide 2.4mg weekly): - Average body weight reduction: 15.2% over 68 weeks - ~32% of patients lost ≥20% of body weight

The SURMOUNT trials (tirzepatide 15mg weekly): - Average body weight reduction: 22.5% over 72 weeks - ~57% of patients lost ≥20% of body weight

Raw numbers favor tirzepatide significantly. But there's important context.

These aren't directly comparable trials. Different patient populations, different trial designs, different time horizons. The SURMOUNT-5 trial was the first true head-to-head comparison, and it confirmed tirzepatide's advantage: participants on tirzepatide lost about 47% more body weight than those on semaglutide over 72 weeks.

But averages obscure individual variation. Some patients lose substantially more on semaglutide than the average tirzepatide patient. Your metabolic profile, GIP receptor expression, and other factors we can't perfectly predict all influence response.

Side Effect Profiles

Both drugs cause similar GI side effects: nausea, vomiting, constipation, and diarrhea — primarily during dose titration in the first 2-3 months. These typically resolve as the body adapts.

Where they differ:

The GIP component in tirzepatide may actually reduce nausea compared to semaglutide alone. Early head-to-head data suggests tirzepatide patients report slightly less nausea at matched efficacy doses. This isn't dramatic, but it matters for tolerability.

Tirzepatide may also have a more pronounced effect on lipids — LDL and triglyceride improvements are somewhat larger compared to semaglutide. This is likely due to the GIP receptor's role in lipid metabolism.

Serious adverse events (pancreatitis, gallbladder disease, thyroid concerns) are rare with both. Absolute contraindications are similar: personal or family history of medullary thyroid carcinoma, MEN2 syndrome.

Who Should Consider Tirzepatide

• Patients who have tried semaglutide and responded partially
• Those with type 2 diabetes (metabolic benefit is additive)
• Patients with dyslipidemia — the lipid effects are pronounced
• Higher BMI patients where the greater weight loss ceiling matters
• Anyone willing to accept slightly higher cost for better average outcomes

Who Should Consider Semaglutide

• First-time GLP-1 users (more clinical data, longer safety track record)
• Patients for whom cost is the primary consideration
• Those with a prior response or familiarity with semaglutide
• Patients where the metabolic difference between the two is unlikely to matter (e.g., modest weight loss goals)

The Compounded Landscape

Both semaglutide and tirzepatide are available as compounded medications through FDA-registered 503B pharmacies. This is legal under FDA compounding regulations when the branded versions are on the FDA drug shortage list — both have been.

At [Marrow](/semaglutide), compounded semaglutide starts at $249/month. [Compounded tirzepatide](/tirzepatide) starts at $299/month. Both include physician oversight, all injection supplies, and free shipping — at 70-80% below brand-name cost.

The Bottom Line

Tirzepatide wins on average weight loss outcomes in head-to-head data. But "average" doesn't mean "for you."

The right choice depends on your starting weight, metabolic profile, prior GLP-1 experience, cost tolerance, and physician judgment. Starting with semaglutide and switching to tirzepatide if response is suboptimal is a common and reasonable strategy. Starting with tirzepatide is also reasonable, especially if you have significant weight to lose and can afford the modest cost difference.

What's not a reasonable strategy: picking based on what celebrities are reportedly on. Talk to a physician who can look at your actual labs and history.